Jiabin Fang , Xiaojie Yang , Lingfeng Chen , Liuying Hong , Yingqiu He , Ji Huang , Jie Lin , Nengluan Xu , Hongru Li
{"title":"Development and validation of prognostic models for bone metastasis in Non-Small cell lung cancer based on Machine learning algorithms","authors":"Jiabin Fang , Xiaojie Yang , Lingfeng Chen , Liuying Hong , Yingqiu He , Ji Huang , Jie Lin , Nengluan Xu , Hongru Li","doi":"10.1016/j.jbo.2025.100716","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Bone is a common site of metastasis in non-small cell lung cancer (NSCLC), yet no validated prognostic model is currently available for patients presenting with bone metastases at diagnosis.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 1,299 NSCLC patients who underwent high-throughput sequencing between 2016 and 2023. Of these, 195 were diagnosed with bone metastases at presentation. Three machine learning algorithms were applied to identify prognostic variables. A nomogram constructed with Cox regression was used to predict overall survival (OS) and was internally validated with 1,000 bootstrap resamples.</div></div><div><h3>Results</h3><div>Four independent prognostic factors were identified, including age, serum calcium, monocyte-to-albumin ratio, and prognostic nutritional index. The nomogram demonstrated strong predictive performance, with areas under the curve (AUCs) of 86.53%, 78.32%, and 77.85% for 6-month, 1-year, and 2-year OS, respectively. Calibration plots showed excellent agreement between predicted and observed survival outcomes.</div></div><div><h3>Conclusion</h3><div>This validated nomogram provides a practical and individualized tool for predicting survival in NSCLC patients with bone metastases at diagnosis, supporting risk stratification and clinical practice.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"55 ","pages":"Article 100716"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212137425000570","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Bone is a common site of metastasis in non-small cell lung cancer (NSCLC), yet no validated prognostic model is currently available for patients presenting with bone metastases at diagnosis.
Methods
We retrospectively reviewed 1,299 NSCLC patients who underwent high-throughput sequencing between 2016 and 2023. Of these, 195 were diagnosed with bone metastases at presentation. Three machine learning algorithms were applied to identify prognostic variables. A nomogram constructed with Cox regression was used to predict overall survival (OS) and was internally validated with 1,000 bootstrap resamples.
Results
Four independent prognostic factors were identified, including age, serum calcium, monocyte-to-albumin ratio, and prognostic nutritional index. The nomogram demonstrated strong predictive performance, with areas under the curve (AUCs) of 86.53%, 78.32%, and 77.85% for 6-month, 1-year, and 2-year OS, respectively. Calibration plots showed excellent agreement between predicted and observed survival outcomes.
Conclusion
This validated nomogram provides a practical and individualized tool for predicting survival in NSCLC patients with bone metastases at diagnosis, supporting risk stratification and clinical practice.
期刊介绍:
The Journal of Bone Oncology is a peer-reviewed international journal aimed at presenting basic, translational and clinical high-quality research related to bone and cancer.
As the first journal dedicated to cancer induced bone diseases, JBO welcomes original research articles, review articles, editorials and opinion pieces. Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject.
The areas covered by the journal include:
Bone metastases (pathophysiology, epidemiology, diagnostics, clinical features, prevention, treatment)
Preclinical models of metastasis
Bone microenvironment in cancer (stem cell, bone cell and cancer interactions)
Bone targeted therapy (pharmacology, therapeutic targets, drug development, clinical trials, side-effects, outcome research, health economics)
Cancer treatment induced bone loss (epidemiology, pathophysiology, prevention and management)
Bone imaging (clinical and animal, skeletal interventional radiology)
Bone biomarkers (clinical and translational applications)
Radiotherapy and radio-isotopes
Skeletal complications
Bone pain (mechanisms and management)
Orthopaedic cancer surgery
Primary bone tumours
Clinical guidelines
Multidisciplinary care
Keywords: bisphosphonate, bone, breast cancer, cancer, CTIBL, denosumab, metastasis, myeloma, osteoblast, osteoclast, osteooncology, osteo-oncology, prostate cancer, skeleton, tumour.